Oncocyte (NYSEMKT:OCX) announces unsuccessful results from a clinical validation study of DetermaDx, a liquid biopsy test aimed at determining whether a lung nodule is suspicious or benign.
The study failed to achieved the main endpoint of a statistically significant improvement in the diagnosis of intermediate-risk nodules, particularly in the 0.8 cm – 22 cm size range, compared to clinical factors used by doctors.
The company will cease further development of the test.
Management will host a conference call today at 5:00 pm ET to discuss the results.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.